U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO	Complete if Known		
INCORMATION DISCLOSURE	Application Number	08/340,664	
OCT 0 7 2004 STATEMENT BY APPLICANT	Filing Date	11/16/1994	
वर्ष । मार्च ही	First Named Inventor	Kaare M. GAUTVIK	
· 6 /	Group Art Unit	1647	
as many sheets as necessary)	Examiner Name	L. Spector	
Shell Adeta 1 of 2	Attorney Docket Number	016777-0310	

	:			U.S. PATENT DOCUMENTS	3	
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (#	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	AT	5,208,041	Known)	SINDREY	05/04/1993	
		·	 			

			_	FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Fr Office	oreign Patent C Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7€
S	A2	wo	84/01173	A1	IMMUNO NUCLEAR CORPORATION	03/29/1984		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ [®]
\mathcal{M}	А3	REPPE ET AL., "Characterization of a K26Q Site-directed Mutant of Human Parathyroid Hormone Expressed in Yeast," <i>The Journal of Biological Chemistry</i> (August 5, 1991), Vol. 266, No. 22, pp. 14198-14201.	
	A4	SINGH ET AL., "Synthesis, secretion and processing of α-factor-interferon fusion proteins in yeast," <i>Nucleic Acids Research</i> , Vol. 12, No. 23, 1984, pp. 8927-8938.	
	A5	MATHAVAN ET AL., "High-level production of human parathyroid hormone in <i>Bombyx mori</i> larvae and BmN cells using recombinant baculovirus," <i>Gene</i> , Vol. 167, 1995, pp. 33-39.	
	A6	NIALL ET AL., "The Amino-Acid Sequence of the Amino-terminal 37 Residues of Human Parathyroid Hormone," <i>Proc. Nat. Acad. Sci.</i> , Vol. 71, No. 2, February 1974, pp. 384-388.0.	
	A7	HØGSET ET AL., "Expression of Human Parathyroid Hormone in Excherichia Coli," <i>Biochemical and Biophysical Research Communications</i> (January 15, 1990), Vol. 166, No. 1, pp. 50-60.	
	A8	HØGSET ET AL., "Expression and Characterization of a Recombinant Human Parathyroid Hormone Secreted by Escherichia coli Employing the Staphylococcal Protein A Promoter and Signal Sequence," <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 13, May 5, 1990, pp. 7338-7344.	-
	A9	KAREEM ET AL., "Translocation and processing of various human parathyroid hormone peptides in Escherichia coli are differentially affected by protein-A-signal sequence mutations," Eur. J. Biochem. (1994), Vol. 220, pp. 893-900.	

Examiner Signature	I Spector	Date Considered	2/3/05	

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, pedude copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

ŋ	UPITER!			•					
R	71 - vo	Substitute for f	om 1449B/	PTO	Complete if Known				
		MITORMATION	N DISCLO	SURE	Application Number	08/340,664			
٠.	OCT 0 7 2004	STATEMENT !	BY APPLI	CANT	Filing Date	11/16/1994			
- 8	OCT OF TOO	<u>E)</u>			First Named Inventor	Kaare M. GAUTVIK			
웪	ď	\$ /			Group Art Unit	1647			
12	To mostle	se as many she	eets as nec	cessary)	Examiner Name	L. Spector			
1	Sheet	se as many she	of	2	Attorney Docket Number	016777-0310			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ [¢]
11	A10	KAREEM ET AL., "A Method for the Evaluation of the Efficiency of signal Sequences for Secretion and Correct N-Terminal Processing of Human Parathyroid Hormone Produced in Escherichia coli," Analytical Biochemistry (1992), Vol. 204, pp. 26-33.	
	A11	KEUTMANN ET AL., "Isolation of Human Parathyroid Hormone," <i>Biochemistry</i> , Vol. 13, No. 8, 1974, pp. 1646-1652.	
V	A12	OLSTAD ET AL., "Differences in Binding Affinities of Human PTH(1-84) Do Not Alter Biological Potency: A Comparison Between Chemically Synthesized Hormone, Natural and Mutant Forms," <i>Peptides</i> , Vol. 15, No. 7, 1994, pp. 1261-1265.	
		·	
	-	•	

Examiner Signature	\mathcal{L}	Socto	Date Considered	2/4/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.